These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. TNF blocker drugs used to fight inflammation go head-to-head. Adalimumab had highest treatment response and remission rates, etanercept has longest drug survival rates; infliximab placed third. Duke Med Health News; 2010 Mar; 16(3):3. PubMed ID: 20461880 [No Abstract] [Full Text] [Related]
23. New drugs for rheumatoid arthritis. Messori A; Santarlasci B; Vaiani M N Engl J Med; 2004 Aug; 351(9):937-8. PubMed ID: 15329436 [No Abstract] [Full Text] [Related]
25. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. Komano Y; Tanaka M; Nanki T; Koike R; Sakai R; Kameda H; Nakajima A; Saito K; Takeno M; Atsumi T; Tohma S; Ito S; Tamura N; Fujii T; Sawada T; Ida H; Hashiramoto A; Koike T; Ishigatsubo Y; Eguchi K; Tanaka Y; Takeuchi T; Miyasaka N; Harigai M; J Rheumatol; 2011 Jul; 38(7):1258-64. PubMed ID: 21498482 [TBL] [Abstract][Full Text] [Related]
26. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Carroll MB; Bond MI Semin Arthritis Rheum; 2008 Dec; 38(3):208-17. PubMed ID: 18221983 [TBL] [Abstract][Full Text] [Related]
27. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Deng A; Harvey V; Sina B; Strobel D; Badros A; Junkins-Hopkins JM; Samuels A; Oghilikhan M; Gaspari A Arch Dermatol; 2006 Feb; 142(2):198-202. PubMed ID: 16490847 [TBL] [Abstract][Full Text] [Related]
29. Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease. Kooloos WM; de Jong DJ; Huizinga TW; Guchelaar HJ Drug Discov Today; 2007 Feb; 12(3-4):125-31. PubMed ID: 17275732 [TBL] [Abstract][Full Text] [Related]
30. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Ollendorf DA; Klingman D; Hazard E; Ray S Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156 [TBL] [Abstract][Full Text] [Related]
31. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150 [TBL] [Abstract][Full Text] [Related]
32. [Merkel cell carcinoma during treatment with TNF-alpha inhibitors: coincidence or warning?]. Linn-Rasker SP; van Albada-Kuipers GA; Dubois SV; Janssen K; Zweers PG Ned Tijdschr Geneeskd; 2012; 156(22):A4464. PubMed ID: 22647228 [TBL] [Abstract][Full Text] [Related]
33. Differential effects of decoy receptor- and antibody-mediated tumour necrosis factor blockage on FoxP3 expression in responsive arthritis patients. Ryder LR; Ryder LP; Bartels EM; Woetmann A; Madsen HO; Ødum N; Danneskiold-Samsøe B; Ribel-Madsen S; Bliddal H APMIS; 2013 Apr; 121(4):337-47. PubMed ID: 23031059 [TBL] [Abstract][Full Text] [Related]
34. TNF- alpha inhibitors. Jackson JM Dermatol Ther; 2007; 20(4):251-64. PubMed ID: 17970890 [TBL] [Abstract][Full Text] [Related]
35. Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases. Lourari S; Prey S; Livideanu C; Jamard B; Lamant L; Cantagrel A; Paul C J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):967-8. PubMed ID: 19192017 [No Abstract] [Full Text] [Related]
36. [The efficacy of the three available anti-tumour necrosis factor therapies in patients with rheumatoid arthritis. A meta-analytic literature review--secondary publication]. Christensen R; Kristensen LE; Geborek P; Danneskiold-Samsøe B; Saxne T; Bliddal H Ugeskr Laeger; 2009 Jun; 171(26):2192-4. PubMed ID: 19678436 [TBL] [Abstract][Full Text] [Related]
37. [Adverse effects of biologic agents in treatment of rheumatoid arthritis--prevention of tuberculosis]. Tomono K; Hashimoto S Nihon Rinsho; 2005 Jan; 63 Suppl 1():573-8. PubMed ID: 15799420 [No Abstract] [Full Text] [Related]
38. Pustular psoriasis following treatment of rheumatoid arthritis with TNF-alpha inhibitors. Egnatios G; Warthan MM; Pariser R; Hood AF J Drugs Dermatol; 2008 Oct; 7(10):975-7. PubMed ID: 19112764 [No Abstract] [Full Text] [Related]
39. [Review of the protective effects of tumor necrosis factor inhibitors in rheumatoid arthritis]. Finckh A; Gabay C; Guerne PA Rev Med Suisse Romande; 2004 Sep; 124(9):547-50. PubMed ID: 15552748 [TBL] [Abstract][Full Text] [Related]
40. Antibodies against mutated citrullinated vimentin fail to predict anti-TNFalpha treatment response in rheumatoid arthritis. Dejaco C; Duftner C; Klotz W; Schirmer M; Herold M Scand J Rheumatol; 2009; 38(1):66-7. PubMed ID: 18759163 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]